Vernal Keratoconjunctivitis Market, Size, Share, Trends, Epidemiology Forecast till 2030

August 26 14:15 2020
Vernal Keratoconjunctivitis Market, Size, Share, Trends, Epidemiology Forecast till 2030

DelveInsight Business Research LLP
DelveInsight’s “Vernal keratoconjunctivitis Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Vernal keratoconjunctivitis, historical and forecasted epidemiology as well as the Vernal keratoconjunctivitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Vernal Keratoconjunctivitis (VKC) is a bilateral, usually seasonally recurrent, allergic inflammation of the conjunctiva, characterized by limbal gelatinous hypertrophy and/or upper tarsal giant conjunctival papillae.

The Vernal keratoconjunctivitis market report provides current treatment practices, emerging drugs, Vernal keratoconjunctivitis market share of the individual therapies, current and forecasted Vernal keratoconjunctivitis market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Vernal keratoconjunctivitis treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

 

Vernal Keratoconjunctivitis Market Insight

The market size of Vernal Keratoconjunctivitis (VKC) in total markets in 2017 was USD 307.89 million

Vernal Keratoconjunctivitis Market Drivers

  • Rise in the Prevalence
  • Disease awareness and diagnosis
  • Research and development

 

Vernal Keratoconjunctivitis Market Barriers

  • Weak emerging drug pipeline
  • Diagnostic Barriers
  • Limited approved therapies

 

Vernal keratoconjunctivitis Market Outlook

Treatment of VKC requires multiple approaches that include conservative measures and pharmacologic treatment. Patients and parents should be made aware of the prolonged duration of disease, its chronic evolution, and possible complications. Treatment should be based on the duration and frequency of symptoms and the severity of corneal involvement.

 

Currently available topical drugs for allergic conjunctivitis belong to several pharmacologic classes, such as vasoconstrictorsantihistaminesmast cell stabilizers, ‘dual-acting’ agents (with antihistaminic and mast cell stabilizing properties), non-steroidal anti-inflammatory agentscorticosteroids, and immunosuppressive drugs.

 

Mast cell stabilizers are the first-line drugs for VKC. Several studies have demonstrated the efficacy of 2% and 4% sodium cromoglicate (DSCG, cromolyn), nedocromil sodium 2%, lodoxamide tromethamine 0.1%, and spaglumic acid 4%.

 

Ocular drugs with antihistaminic activity may offer therapeutic advantages to patients with allergic conjunctivitis, including VKC, by inhibiting proinflammatory cytokine secretion from conjunctival epithelial cells. The first-generation antihistamines pheniramine and antazoline have a long safety record. The newer antihistamines such as levocabastine hydrochloride 0.5% and emedastine difumarate 0.05% have a longer duration of action (4–6 h) and are better tolerated than their predecessors.

 

A meta-analysis of randomized clinical trials in VKC showed a large number of studies evaluated the efficacy of common anti-allergic eye drops (levocabastinelodoxamidemipragosideN-acetyl aspartyl glutamic acidnedocromil sodiumDCG). Among these, lodoxamide appeared to be the most effective.

 

Papilock mini and Verkazia both produced by Santen (Osaka, Japan) are specifically indicated for the treatment of VKC.

Generally, NSAIDs employed in ocular allergy treatment inhibit both cyclooxygenase (COX)-1 and COX-2 enzymes. Also, Ketorolacdiclofenac and pranoprofen may be valid alternatives to steroids, since they have a proven effect on itching, intercellular adhesion molecule-1 expression, and tear tryptase levels. Indomethacin 1%, ketorolac 0.5%, and diclofenac 0.1% have shown effectiveness in the treatment of VKC.

 

Aspirin 0.5–1 g/day has been shown as a steroid-sparing factor in the treatment of VKC; however, it should be used with caution because of the well-known possible side effects.

 

In severe cases, systemic treatment with T-lymphocyte signals transduction inhibitors such as Cyclosporine A or tacrolimus may ameliorate both the dermatologic and ocular manifestations in critical patients who are refractory to conventional treatment.

Omalizumab, an anti-IgE recombinant, humanized, non-anaphylactogenic antibody, directed against the receptor-binding domain of IgE, may be used in VKC patients with high levels of total serum IgE. Calcineurin inhibitors are off-label treatments in the European Union.

 

As discussed, the current treatment for VKC depends solely on the use of antihistamines, mast cell inhibitors, and several other classes. But till now the treatment is only supportive and is not that effective. But due to the advancement of technology and a better understanding of the disease, several companies are trying to modify the treatment of VKC.

 

Request for sample pages
Table of contents

 

1. Key Insights

 

2. Executive Summary of Vernal keratoconjunctivitis (VKC)

 

3. Vernal keratoconjunctivitis (VKC): Market Overview at a Glance

 

3.1. Total Market Share (%) Distribution of VKC in 2017

 

3.2. Total Market Share (%) Distribution of VKC in 2030

 

4. Disease Background and Overview: Vernal keratoconjunctivitis (VKC

 

5. Case Report

 

6. Epidemiology and Patient Population

 

7. United States Epidemiology

 

8. EU5 Epidemiology

 

8.1. Assumptions and Rationale

 

8.2. Germany Epidemiology

 

8.3. France Epidemiology

 

8.4. Italy Epidemiology

 

8.5. Spain Epidemiology

 

8.6. United Kingdom Epidemiology

 

9. Japan Epidemiology

 

10. MEA Region Epidemiology

 

10.1. Assumptions and Rationale

 

10.2.Saudi Arabia Epidemiology

 

10.3.Egypt Epidemiology

 

11. China Epidemiology

 

12. Russia Epidemiology

 

13. Current Treatment and Medical Practices

 

13.1. Treatment of VKC

 

13.2. Practical management of VKC

 

13.3. Treatment Guidelines

 

14. Unmet Needs

 

15. Marketed Drugs

 

15.1. Verkazia/Verkacia: Santen

15.2. Lodoxamide/Alomide: Novartis Pharmaceuticals/Alcon

 

15.3. Talymus/Tacrolimus: Senju Pharmaceutical

 

16. Emerging Drugs

 

16.1. Antolimab (AK002): Allakos

 

16.2. Bertilimumab/iCo-008: iCo Therapeutics

 

16.3. Nomacopan: Akari Therapeutics

 

17. Vernal Keratoconjunctivitis (VKC): 7MM Market Analysis

 

18. United States

 

19. EU-5 countries

 

19.1.Germany Market Size

 

19.2.France Market Size

 

19.3.Italy Market Size

 

19.4.Spain Market Size

 

19.5.United Kingdom Market Size

 

20. Japan

 

20.1. Japan Market Size

 

21. MEA countries Market Outlook

 

21.1.Saudi Arabia Market Size

 

21.2.Egypt Market Size

 

22. China: Market Outlook

 

22.1. China Market Size

 

23. Russia Market Outlook

 

23.1. Russia Market Size

 

24. Market Drivers

 

25. Market Barriers

 

26. Reimbursement and Market Access

 

27. SWOT Analysis

 

28. KOL Views

 

29. Appendix

 

30. DelveInsight Capabilities

 

31. Disclaimer

 

32. About DelveInsight

 

Media Contact
Company Name: DelveInsight
Contact Person: Priya Maurya
Email: Send Email
Phone: +919650213330
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/


Warning: count(): Parameter must be an array or an object that implements Countable in /home/mizorammail/mangalore-online.in/wp-content/themes/gadgetine-theme/includes/single/post-tags-categories.php on line 7